Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Selecta Biosciences, Inc. (SELB : NSDQ)
 
 • Company Description   
Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States.

Number of Employees: 58

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.80 Daily Weekly Monthly
20 Day Moving Average: 1,676,045 shares
Shares Outstanding: 151.81 (millions)
Market Capitalization: $120.81 (millions)
Beta: 1.36
52 Week High: $5.28
52 Week Low: $0.65
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -3.92% 5.20%
12 Week -58.33% -53.17%
Year To Date -75.59% -70.18%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
65 Grove Street
-
Watertown,MA 02472
USA
ph: 617-923-1400
fax: 617-924-3454
sarah@sternir.com https://selectabio.com
 
 • General Corporate Information   
Officers
Carsten Brunn - President and Chief Executive Officer
Kevin Tan - Chief Financial Officer
Carrie S. Cox - Director
Goran A. Ando - Director
Timothy C. Barabe - Director

Peer Information
Selecta Biosciences, Inc. (CORR.)
Selecta Biosciences, Inc. (RSPI)
Selecta Biosciences, Inc. (CGXP)
Selecta Biosciences, Inc. (BGEN)
Selecta Biosciences, Inc. (GTBP)
Selecta Biosciences, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 816212104
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 151.81
Most Recent Split Date: (:1)
Beta: 1.36
Market Capitalization: $120.81 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.08 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.28 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.17
Price/Cash Flow: -
Price / Sales: 1.12
EPS Growth
vs. Year Ago Period: 68.18%
vs. Previous Quarter: -75.00%
Sales Growth
vs. Year Ago Period: 207.68%
vs. Previous Quarter: 13.57%
ROE
03/31/22 - -33.56
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -2.84
12/31/21 - -23.09
09/30/21 - -33.74
Current Ratio
03/31/22 - 3.31
12/31/21 - 2.00
09/30/21 - 1.59
Quick Ratio
03/31/22 - 3.31
12/31/21 - 2.00
09/30/21 - 1.59
Operating Margin
03/31/22 - -4.30
12/31/21 - -46.43
09/30/21 - -86.74
Net Margin
03/31/22 - 25.63
12/31/21 - -30.19
09/30/21 - -79.55
Pre-Tax Margin
03/31/22 - 40.41
12/31/21 - -11.43
09/30/21 - -55.96
Book Value
03/31/22 - 0.37
12/31/21 - 0.19
09/30/21 - -0.16
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.45
12/31/21 - 0.87
09/30/21 - -
Debt-to-Capital
03/31/22 - 30.99
12/31/21 - 46.63
09/30/21 - -
 

Powered by Zacks Investment Research ©